Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli-2 (EXPECT-2)

计划入组 238 人 · 首次发布于 2019 年 10 月 7 日

A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health

计划入组 836 人 · 首次发布于 2019 年 1 月 28 日

ExPECT: Extraperitoneal End Colostomy Trial

计划入组 23 人 · 首次发布于 2021 年 12 月 20 日

E coli bioconjugate vaccine (GSK/Janssen)

JNJ-78901563

ExPEC10V

Charter Hall Group

iShares Core Composite Bond ETF

United States

Notable Labs

Israel

Sanofi and J&J Join Forces in $175M Deal to Combat E. coli Sepsis with Novel Vaccine

CARB-X Awards $1.1 Million to Phiogen for Novel Bacteriophage Treatment Against Drug-Resistant E. coli Bloodstream Infections

Expecto Health Science Partners with VertisPro to Deploy AI-Driven Patient Recruitment in Asia-Pacific Clinical Trials